Recent Updates
Recently added Catalysts
HAE Positive Sentiment Score: 70/100

Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Key Takeaway: Haemonetics Corporation has made its financial results for the third quarter of fiscal 2026 available on its Investor Relations website. The results cover the period ending December 27, 2025. A conference call and webcast are scheduled for February 5, 2026, at 8:00 a.m. ET to discuss these results.

Market Sentiment Analysis

POSITIVE FACTORS

  • Haemonetics reported financial results for Q3 FY 2026.
  • The company is hosting a conference call to discuss results.
  • Innovative solutions in healthcare are highlighted.

Full Press Release Details

Financial release and supplemental presentation accessible online
BOSTON,Feb. 5, 2026/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website atwww.haemonetics.com.
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 5, 2026.
Conference Call and Webcast Information:
A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on February 5, 2026 and will remain accessible for one year via the webcast link above.
Earnings Materials:Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast:
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visitwww.haemonetics.com.
Investor Contacts:
Olga Guyette, Vice President-Investor Relations & Treasury David Trenk, Manager-Investor Relations
(781) 356-9763 (203) 733-4987
olga.guyette@haemonetics.com
david.trenk@haemonetics.com
Media Contact:
Josh Gitelson, Sr. Director-Global Communications
(781) 356-9776
josh.gitelson@haemonetics.com
SOURCE Haemonetics Corporation

Frequently Asked Questions

When are Haemonetics' Q3 FY 2026 results available?

The financial results for Q3 FY 2026 are available on the Investor Relations website.

What time is the conference call for Q3 results?

The conference call is scheduled for 8:00 a.m. ET on February 5, 2026.

Where can I access the conference call replay?

The replay will be available starting at 11:00 a.m. ET on February 5, 2026.

What does Haemonetics focus on?

Haemonetics focuses on improving healthcare quality and efficiency through innovative solutions.

Last updated: Feb 5, 2026